A pilot single-arm, pragmatic trial in progress of in-home versus in-clinic subcutaneous nivolumab administration through Cancer Care (connected access and remote expertise) Beyond Walls (CCBW) program.

作者：Dina Elantably, Jeremy Jones, Yanyan Lou, Gina L. Mazza, Chanice Howard, Sunnie Confiado, Amber Baskin, Alexis Jackson, Angela Hazel Fritsche, Kai Castrezana Lopez, Jade Brown, Luci Nolan, Dustin Chapin, Gregory Beliles, Nathan Smith, Winston Tan, Mohamed A. Kharfan‐Dabaja, Grzegorz S. Nowakowski, Cheryl L. Willman, Roxana Dronca · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.tps1657 · 被引用次数：1 · 研究领域：Economic and Financial Impacts of Cancer、Health Systems, Economic Evaluations, Quality of Life、Cancer Immunotherapy and Biomarkers

TPS1657 Background: Cancer treatments are traditionally administered in clinical settings, which can isolate patients from their familiar environments and exacerbate physical, psychosocial, and financial burdens. Travel requirements further amplify these challenges, particularly for underserved populations. Studies indicate that patients prefer receiving care at home, and international models have demonstrated the safety of home-delivered chemotherapy since the 1990s; however, no U.S. clinical trial data exists. In response, Mayo Clinic has developed the Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) program, a distributed cancer care delivery model that expands access to quality cancer care by bringing it to the home environment, providing in-home cancer treatment, lab testing, telemedicine, and community paramedic support. This trial evaluates the safety, acceptability, and impact of home-based subcutaneous (SC) nivolumab (Nivo) administration compared to in-clinic treatment within the CCBW initiative. Methods: This open-label, single-arm trial evaluates the impact of SC Nivo administration location—home versus infusion center—on patient reported cancer care experience, patient-preferred treatment location, acceptability, safety, and patient-reported outcomes. Eligible adult patients (ECOG 0-1) receiving IV Nivo for an FDA-approved indication and residing within 75 miles of Mayo Clinic Florida will transition to SC Nivo, receiving two initial in-cli...